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Traditional therapeutic interventions against abnormal gene expression in disease states at the level of
expressed proteins are becoming increasingly difﬁcult due to poor selectivity, off-target effects and
associated toxicity. Upstream catalytic targeting of speciﬁc RNA sequences offers an alternative platform
for drug discovery to achieve more potent and selective treatment through antisense interference with
disease-relevant RNAs. We report a novel class of catalytic biomaterials, comprising amphipathic RNA-
cleaving peptides placed between two RNA recognition motifs, here demonstrated to target the TJC
loop and 30- acceptor stem of tRNAPhe. These unique peptidyl-oligonucleotide ‘dual’ conjugates (DCs)
were created by phosphoramidate or thiol-maleimide conjugation chemistry of a TJC-targeting oligo-
nucleotide to the N-terminus of the amphipathic peptide sequence, followed by amide coupling of a 30-
acceptor stem-targeting oligonucleotide to the free C-terminal carboxylic acid functionality of the same
peptide. Hybridization of the DCs bearing two spatially-separated recognition motifs with the target
tRNAPhe placed the peptide adjacent to a single-stranded RNA region and promoted cleavage within the
‘action radius’ of the catalytic peptide. Up to 100% cleavage of the target tRNAPhe was achieved by the best
candidate (i.e. DC6) within 4 h, when conformational ﬂexibility was introduced into the linker regions
between the peptide and oligonucleotide components. This study provides the strong position for future
development of highly selective RNA-targeting agents that can potentially be used for disease-selective
treatment at the level of messenger, micro, and genomic viral RNA.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
RNA-targeting agents are recognized as a promising alternative
to conventional small-molecule therapeutic strategies, suffering
from poor target selectivity, as a result of their small size and the
limited number of chemical functional groups available in low
molecular weight drugs. Poor selectivity may ultimately lead to
toxicity and other off-target effects undesirable in humans [1,2].
Silencing disease-speciﬁc genes at the level of expressed RNA may
offer an opportunity to reduce these undesirable drug-related sideC, dual conjugate; POC, pep-
thiocyanate; MALDI, matrix-
RT, room temperature; TSP,
c.uk (E.V. Bichenkova).
d equally to the work.
r Ltd. This is an open access articleeffects, commonly associated with poor drug selectivity and/or the
high dosages necessary to achieve a therapeutic effect. Also, the
traditional drug discovery process against pathogenic proteins re-
quires laborious virtual and/or experimental screening of
numerous drug leads against each target. In contrast, the devel-
opment of RNA therapies is facilitated by a logical and common
design platform of antisense targeting based on a highly-
predictable 3D structural organisation of nucleic acids. Moreover,
RNA-targeting interventions may be extended to a number of other
biologically-signiﬁcant RNAs (e.g., miRNAs), which are implicated
in many pathological disease processes, including various types of
cancer (breast [3], ovarian [4], lung cancer [5]), cardiovascular [6,7]
and neurodegenerative diseases [8]. Potential targets also include
messenger-RNA transcripts (e.g.,mRNA encoding clusterin, an anti-
apoptotic chaperone protein upregulated in cancer cells [9,10]) or
viral-genomic RNAs (e.g., HIV [11,12] or Ebola [13,14]). Sequence-
speciﬁc targeting at the RNA level may considerably reduce theunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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of pathological proteins, and the associated subsequent lengthy
process of lead identiﬁcation using ligand-, mechanism- or
receptor-based rational drug design.
Currently, siRNA and antisense oligonucleotides (ASO) are the
two main approaches to target disease at the level of messenger
RNA. The discovery of siRNA in 1999 [15] led to the incorporation of
a number of specialist biotechnology companies (e.g., Sirna Thera-
peutics, Dicerna Pharmaceuticals, Alnylam Pharmaceuticals, Sir-
naomics Inc.). However, various issues persist and prevent the
translation of siRNA into the clinic including: (i) undesirable im-
mune responses triggered by siRNA [16e18], (ii) saturation of the
RNA-induced silencing-complex (RISC) [19] leading to upregulation
of disease causing proteins, and (iii) poor cellular delivery
[18,20e22]. This has led to a number of large pharmaceutical
companies discontinuing their siRNA research and development
pipeline [23]. Antisense oligonucleotides on the other hand have
reached clinical application for a number of treatments including
Fomivirsen [24] (Vitravene®) for the treatment of cytomegalovirus
retinitis andMipomersen [25] (Kynamro®) for homozygous familial
hypercholesterolemia. However, their mechanism of action is often
based on a 1:1 binding stoichiometry and thus requires a relatively
high dosage of ASO to silence the target mRNA transcript effectively
[26].
An alternative approach for irreversible targeting of RNA se-
quences is based on the use of artiﬁcial (or chemically-engineered)
ribonucleases. This class of supramolecular biomaterials is
designed to mimic the active centres of natural enzymes to be
capable of accelerating the spontaneous, irreversible degradation of
the RNA phosphodiester backbone. Peptidyl-oligonucleotide con-
jugates (POCs) are a particular class of chemical ribonucleases,
which catalyse the hydrolytic cleavage of the RNA phosphodiester
backbone [27e30]. POCs typically consist of a short (e.g., 6 to 17-
mer) targeting motif and a covalently-attached amphiphilic pep-
tide (5e10-mer) with alternating leucine and arginine residues. The
antisense motif is able to target a speciﬁc RNA and direct the cat-
alytic peptide to the desired RNA region, thus increasing its effec-
tive concentration in the vicinity of the cleavage site. The overall
cationic nature of the peptide sequence, due to the presence of
arginine residues, allows it to interact with the negatively-charged
phosphodiester backbone within the target RNA region, and to
promote RNA hydrolysis without the need for exogenous species
such as enzymes or cofactors (e.g., RISC, RNase H).
Recently, we demonstrated [30] complete site-selective cleav-
age of model RNA (yeast tRNAPhe) under physiological conditions
over a 12e24 h period without the need for exogenous species (e.g.,
metal ions, additional enzymes) and at POC:RNA concentration
ratio of 20:1. The artiﬁcial ribonucleases there were constructed
from peptidyl-oligonucleotide conjugates (POCs) containing a short
amphiphilic peptide sequence (consisting of leucine, arginine and
glycine amino acid residues) and a 17-mer oligodeoxynucleotide
recognition fragment (GATCGAACACAGGACCT), which were
coupled together chemically by a phosphoramidate bond between
the peptide N-terminus and the 50-terminal phosphate group.
Notably, RNA cleavage was observed only when the peptide and
oligonucleotide constituents were covalently attached to form a
catalytically-active peptidyl-oligonucleotide conjugate. A signiﬁ-
cant discovery of this study [30] and some previous investigations
[28,31] is that the structural properties of the joint molecular blocks
and their molecular ﬂexibility inﬂuenced the functional perfor-
mance of these supramolecular catalysts, and thus should be
considered in the future design of novel chemical ribonucleases. In
order for peptide-mediated RNA-cleavage to occur, the peptide
must adopt a conformation which can enhance the natural spon-
taneous hydrolysis of RNA [32,33]. Accordingly, this reportconsiders whether increasing the ﬂexibility of the peptide at the
point of its restriction (i.e., at the rigid oligonucleotide motif in its
hybridised double-stranded state) favours the number of non-
covalent interactions, with the target RNA sequence, to promote
the required ‘in-line’ geometry necessary for 20OH attack of the
bridging phosphorus atom.
Herein, we designed and synthesized such a new generation of
POCs, which places the catalytic peptide in-between two oligo-
deoxynucleotide recognition motifs (see Fig. 1). In order to inves-
tigate the role of conformational ﬂexibility on the hybridization
properties and catalytic performance of these conjugates against
RNA, we varied the structure and length of the linker groups and
recognition motifs. These novel ‘dual’ conjugates were targeted
towards the TJC loop and 30- overhang of yeast tRNAPhe. Although
not a clinically relevant RNA target, tRNAPhe contains many of the
secondary structural elements present in messenger-, micro- or
viral-RNA sequences and, therefore, serves well as a proof of concept
target for the development of these novel DCs. Furthermore, many
chemical nucleases have been validated against this target, allow-
ing direct comparison of RNA cleavage activity with other work
[31,34]. Through chemical modiﬁcation of peptide N- and C-
termini with 30- or 50- modiﬁed oligodeoxynucleotides, a library of
11 novel dual conjugates (DCs) have been synthesized, isolated and
fully characterized. We present here their RNA hybridization and
cleavage properties against tRNAPhe under physiological conditions
and report a remarkably high RNA cleavage activity of the best
structural variant of the DCs.
2. Materials and methods
2.1. Chemicals, reagents and facilities
Reagents and materials were purchased from Sigma-Aldrich
(UK), unless otherwise indicated. Oligodeoxynucleotides were
purchased from AtdBio Ltd. (Southampton, UK). Fmoc-Gly-Rink
Amide-MBHA peptide resin was purchased from Eurogentec Ltd.
(Liege, Belgium). T7 RNA polymerase and plasmid p67YF0 were
kindly provided by Dr. S. Khodyreva and Dr. N. Moor, respectively
(Institute of Chemical Biology and Fundamental Medicine, Siberian
Branch of the Russian Academy of Sciences). RNase T1 was pur-
chased from Fermentas (Lithuania), and restriction enzymes Bst2UI
and Fok1 were purchased from SibEnzyme Ltd. (Russian Federa-
tion). pHIV-1 was kindly provided by Prof. H.J. Gross (University of
Würzburg, Germany).
Puriﬁcation of peptides and peptidyl-oligonucleotide conju-
gates were performed using Agilent 1100 HPLC system (Agilent
Technologies, Santa Clara, CA). Reversed phase chromatography
was carried out in a similar way as described earlier [30] using a
semi-preparative column Luna C18 (Phenomenex; CA, USA). Ion-
exchange chromatography (IEX) puriﬁcations of dual-conjugates
were carried out using a Clarity Oligo-WAX (150  4.6 mm, 10 Å
pore size, Phenomenex; CA, USA) column. Mass spectrometry ser-
vice was kindly provided by EPSRC National Mass Spectrometry
Centre (Swansea, UK). Some MALDI mass spectra of ‘mono’ and
‘dual’ peptidyl-oligonucleotide conjugates were recorded using a
Bruker Daltonics Ultraﬂex TOF/TOF mass spectrometer (MA, USA)
at Manchester Institute of Biotechnology (Manchester, UK) using
the method described earlier in Ref. [30]. 1H and 31P NMR spectra
were recorded using Bruker Avance IIþ 400 NMR spectrometer
(400 MHz) equipped with TopSpin 3.2 software for NMR data
acquisition and processing.
2.2. Peptide synthesis, puriﬁcation and characterization
Peptides [LR]2G, [LR]3G, [LR]4G, Mal-[LR]4G and Mal-[LRLRG]2
Fig. 1. A. Design concept of ‘dual’ peptidyl-oligonucleotide conjugate, which incorporates catalytic peptide (green) as a linker between two oligodeoxyribonucleotide recognition
motifs. B. Representative structure of the catalytic peptide incorporated into ‘dual’ conjugates DC4-DC6 and DC8-DC11, containing [Leu-Arg]n building blocks. C. Secondary structure
of tRNAPhe (in-vitro transcript) along with the TJC- and acceptor stem binding sites targeted by Recognition Motif A (red) and B (blue), respectively. Solid lines represent regions
targeted by all recognition motifs. Dotted lines show regions targeted by extended recognition motifs as listed in Table 1. The peptide (green) connecting Recognition Motifs A and B
reside close to the 65GACAC61 target sequence. Red arrows show cleavage sites induced in tRNAPhe by DC7, whereas black arrows and black squares show major and minor cleavage
sites, respectively, induced by DC6.
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protocol [30]. N-terminal maleimide modiﬁcation was achieved
with N-maleoyl-b-alanine (101 mg, 0.6 mmol) using the coupling
conditions identical to those described in Ref. [30].
Analytical data for [LR]2G and [LR]4G peptides acquired from
mass spectrometry and 1H NMR has been previously reported [30]
(see data for (5) and (4), respectively).2.2.1. [LR]3G
(188 mg, yield 70%). ESI-MS: m/z ¼ 442.3 for [Mþ2H]2þ, 295.2
for [Mþ3H]3þ (MW ¼ 882.59 calcd. for [C38H74N16O8]). 1H NMR
(D2O with TSP (0.1 mM), 400 MHz): d 0.87e0.96 (m, 18H, Leu-Hd),
1.51e1.96 (m, 21H, Leu-Hb,g, Arg-Hb,g), 3.18e3.23 (s, 6H, Arg-Hd),
3.82 (s, 2H, Gly-H), 4.02 (t, 1H, J ¼ 10.12 Hz, N-Leu-Ha), 4.31e4.42
(m, 5H, Leu/Arg-Ha).2.2.2. Mal-[LR]4G
(250 mg, yield 70%). ESI-MS: m/z ¼ 652.4 for [Mþ2H]2þ, 435.3
for [Mþ3H]3þ (MW ¼ 1302.80 calcd. for [C57H102N22O13]). 1H NMR
(D2O with TSP (0.1 mM), 400 MHz): d 0.87e0.96 (m, 24H, Leu-Hd),
1.50e1.91 (m, 28H, 8 Arg-Hb, 8 Arg-Hg, 8 Leu-Hb, 4 Leu-Hg),
2.42e2.66 (m, 2H, Mal-Hb), 3.16e3.24 (m, 8H, Arg-Hd), 3.73e3.90
(m, 2H, Mal-Ha) 3.86e4.44 (m, 10H, 2  Gly-H, 8  Leu/Arg-Ha),
6.82 (s, 2H, Mal-H).2.2.3. Mal-[LRLRG]2
(260 mg, yield 72%). ESI-MS: m/z ¼ 680.9 for [Mþ2H]2þ, 454.3
for [Mþ3H]3þ (MW ¼ 1359.82 calcd. for [C59H105N23O14]). 1H NMR
(D2O with TSP (0.1 mM), 400 MHz): d 0.84e0.95 (m, 24H, Leu-Hd),
1.45e1.91 (m, 28H, 8 Arg-Hb, 8 Arg-Hg, 8 Leu-Hb, 4 Leu-Hg),
2.46e2.65 (m, 2H, Mal-Hb), 3.18e3.24 (m, 8H, Arg-Hd), 3.71e3.87
(m, 2H, Mal-Ha) 3.90e4.39 (m, 12H, 4  Gly-H, 8  Leu/Arg-Ha),
6.86 (s, 2H, Mal-H).2.3. Single conjugate synthesis (Method 1)
In order to attach peptide [LR]2G, [LR]3G or [LR]4G to oligonu-
cleotide pGATCGAACACAG (1) containing 50-terminal phosphate
group we used Method 1, which was an adaptation of the previ-
ously described protocol [30] for conjugation of 50-phosphate
modiﬁed oligonucleotides with peptides containing free N-termi-
nal amine groups (see Scheme S1, ‘Supplementary Data’).2.4. Single conjugate synthesis (Method 2)
Thiol (disulphide protected) modiﬁed oligonucleotide, Thiol-
GATCGAACACAG (2), Thiol-GGATCGAACACAG (3) or Thiol-
TGGATCGAACACAG (4) (0.12 mmol) in phosphate-buffered saline
at pH 7 (200 mL) was reduced by addition of 3% (w/v) tris(2-
carboxyethyl)phosphine (TCEP; 12 mL) and shaken for 1 h. The pH
was then adjusted to pH 7 with NaOH (0.5 M). Maleimide-modiﬁed
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minimal volume of DMSO (z15 mL) and added dropwise to the
oligonucleotide solution with gentle agitation (see Scheme S2,
‘Supplementary Data’). The reactions were mechanically shaken
for 2 h at RT. The conjugation product along with the starting
oligonucleotide was precipitated with LiClO4 (4% w/v in acetone) as
described in detail in Ref. [30]. Before attachment of the second
oligonucleotide motif, the ‘single’ conjugates were puriﬁed by RP-
HPLC in a similar way described earlier in Ref. [30].
2.5. Dual conjugate synthesis
Single conjugate (0.1 mmol) dissolved in 0.1M 2-(N-morpholino)
ethanesulfonic acid buffer pH 6 (MES; 50 mL) was mixed with an
equal quantity (0.1 mmol) of aminohexyl-modiﬁed oligonucleotide
(oligonucleotides 5, 6, 7, 8 or 9) dissolved in MES (20 mL),
N-hydroxysuccinimide (NHS; 0.16 mmol) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC; 1.6 mmol) (see Scheme
S3, ‘Supplementary Data’). The reaction mixtures were left over-
night at RT, when they were diluted to 1 mL with 0.05 M LiClO4 and
puriﬁed directly by IEX (see below) or by RP-HPLC as described
earlier in Ref. [30].
2.6. Dual conjugate puriﬁcation by IEX
Conjugates were puriﬁed by IEX directly from reactionmixtures.
The ﬂow rate was maintained at 2.0 mL/min using 10 mM Tris-Cl
(pH 7.25) and 10% AcCN as eluent A and 10 mM Tris-Cl (pH 7.25),
2 M NaCl and 10% AcCN as eluent B. The absorbance was monitored
at 260 nm and the following gradient was applied: 100% A for
2 min, 0% B to 80% B in 18 min for DC1 - DC3; 100% A for 3 min, 0% B
to 100% B in 23 min for DC8 - DC9; 100% A for 5 min, 0% B to 100% B
in 32 min for DC4 - DC7, DC10 - DC11. Product peaks were collected
and then desalted using RP-HPLC with 0.05 M LiClO4 as eluent A
and 0.05 M LiClO4 in AcCN as eluent B. The absorbance was
monitored at 260 nm and the following gradient was applied: 100%
A for 3 min, 0% B to 100% B in 10 min. Product peaks were collected,
freeze-dried and combined. The excess salt was removed by dis-
solving the material in H2O (100 mL) and precipitating in 4% LiClO4
in acetone (w/v) (1.8 mL) overnight. The product was collected by
centrifugation (13400 rpm, 4 min), air-dried and then freeze-dried.
2.7. Dual conjugate characterization
Identity and purity of all ‘dual’ peptidyl-oligonucleotide conju-
gates have been conﬁrmed by IEX or RP-HPLC, Urea-PAGE (Fig. S1,
‘Supplementary Data’), 31P and/or 1H NMR spectroscopy (Fig. 3
and Fig. S2, ‘Supplementary Data’) and mass spectrometry
(Fig. S3, ‘Supplementary Data’). 1H NMR analysis was carried out on
all DCs; however, the H30/H40/H50/H500 sugar ring proton regions
(3.5e5.0 ppm) were not analysed due to suppression of residual
water signal at 4.8 ppm. 31P NMR analysis was carried out only on
DCs 1, 2 and 3 since it cannot be used as a characterization tool for
DCs 4 to 11 due to the nature of 50-thiol modiﬁcation. Urea-PAGE
analysis of the synthesized DCs illustrates their purity (98e100%.)
and reduced electrophoretic mobility versus the intermediate
‘single’ POCs and unconjugated oligonucleotide (see Fig. S1 in the
‘Supplementary Data’). Mass spectrometry analysis of DCs was
carried out using matrix-assisted laser desorption ionization
spectroscopy (MALDI). DCs were identiﬁed as mono- or di-sodium/
potassium adducts with experimental masses in agreement with
theoretical calculations.
2.7.1. DC1 (5
0
1-[LR]2G-5 3
0
)
(67 nmol, yield 67%). MALDI-MS: m/z ¼ 7914 [MþH]þ(MW ¼ 7913 calcd. for [C259H347N104O143P23]). 1H NMR (D2O with
TSP (0.01 mM), 400 MHz): d 0.62e0.93 (m, 12H, Leu-Hd), 1.14e3.16
(m, 92H, 23  H20 and 23  H200 sugar ring protons, 5  CH3 of
5  dT, 4Arg-Hb, 4  Arg-Hd, 4  Arg-Hg, 4  Leu-Hb, 2  Leu-Hg,
6  CH2 (aminohexyl linker), 1  CH (aminohexyl linker)),
5.32e6.33 (m, 27H, 23  H10 sugar ring protons, 4  H5 of dC),
7.25e8.28 (m, 30H, 30 Ar-H fromdG( 7), dA( 14), dC( 4) and
dT( 5)). 31P{1H} NMR (D2O,160MHz): d1.50 to0.39 (22P, PO4),
6.13 (1P, N-PO3). No sample reference was used for 31P NMR anal-
ysis. It was carried out to observe the relative shift of the 31P-N
resonance.
2.7.2. DC2 (5
0
1-[LR]3G-5 3
0
)
(86 nmol, yield 86%). MALDI-MS: m/z ¼ 8184 [MþH]þ
(MW ¼ 8183 calcd. for [C271H370N109O145P23]). 1H NMR (D2O with
TSP (0.01 mM), 400 MHz): d 0.61e0.91 (m, 18H, Leu-Hd), 1.14e3.18
(m, 101H, 23  H20 and 23  H200 sugar ring protons, 5  CH3 of
5  dT, 6Arg-Hb, 6  Arg-Hd, 6  Arg-Hg, 6  Leu-Hb, 3  Leu-Hg,
6  CH2 (aminohexyl linker), 1  CH (aminohexyl linker)),
5.36e6.31 (m, 27H, 23  H10 sugar ring protons, 4  H5 of dC),
7.25e8.34 (m, 30H, 30  Ar-H from dG(  7), dA(  14), dC (  4)
and dT (  5)). 31P{1H} NMR (D2O, 160 MHz): d 1.54 to 0.41 (22P,
PO4), 5.86 (1P, N-PO3). No sample reference was used for 31P NMR
analysis. It was carried out to observe the relative shift of the 31P-N
resonance.
2.7.3. DC3 (5
0
1-[LR]4G-5 3
0
)
(71 nmol, yield 71%). MALDI-MS: m/z ¼ 8453 [MþH]þ
(MW ¼ 8452 calcd. for [C283H393N114O147P23]). 1H NMR (D2O with
TSP (0.01 mM), 400 MHz): d 0.52e0.86 (m, 24H, Leu-Hd), 1.07e3.15
(m, 110H, 23  H20 and 23  H200 sugar ring protons, 5  CH3 of
5  dT, 8Arg-Hb, 8  Arg-Hd, 8  Arg-Hg, 8  Leu-Hb, 4  Leu-Hg,
6  CH2 (aminohexyl linker), 1  CH (aminohexyl linker)),
5.29e6.25 (m, 27H, 23  H10 sugar ring protons, 4  H5 of dC),
7.19e8.29 (m, 30H, 30 Ar-H from dG( 7), dA( 14), dC( 4) and
dT( 5)). 31P{1H} NMR (D2O,160MHz): d1.79 to0.71 (22P, PO4),
5.92 (1P, N-PO3). No sample reference was used for 31P NMR anal-
ysis. It was carried out to observe the relative shift of the 31P-N
resonance.
2.7.4. DC4 (5
0
4-Mal-[LRLRG]2e5 3
0
)
(67 nmol, yield 67%). MALDI-MS: m/z ¼ 9430 [MþH]þ
(MW ¼ 9429 calcd. for [C318H440N123O165P25S]). 1H NMR (D2O with
TSP (0.01 mM), 400 MHz): d 0.72e0.89 (m, 24H, Leu-Hd), 1.15e3.24
(m, 131H, 25  H20 and 25  H200 sugar ring protons, 6  CH3 of
6  dT, 8Arg-Hb, 8  Arg-Hd, 8  Arg-Hg, 8  Leu-Hb, 4  Leu-Hg,
6  CH2 (aminohexyl linker), 1  CH (aminohexyl linker), 6  CH2
(thiohexyl linker), 2 Mal-Hb), 5.40e6.33 (m, 29H, 25  H10 sugar
ring protons, 4  H5 of dC), 7.25e8.35 (m, 32H, 32  Ar-H from
dG(  8), dA(  14), dC(  4) and dT(  6)).
2.7.5. DC5 (5
0
3-Mal-[LRLRG]2e5 3
0
)
(79 nmol, yield 79%). MALDI-MS: m/z ¼ 9167 [MþHþACN]þ
(MW ¼ 9125 calcd. for [C308H427N121O158P24S]). 1H NMR (D2O with
TSP (0.01 mM), 400 MHz): d 0.72e0.89 (m, 24H, Leu-Hd), 1.15e3.24
(m, 126H, 24  H20 and 24  H200 sugar ring protons, 5  CH3 of
5  dT, 8Arg-Hb, 8  Arg-Hd, 8  Arg-Hg, 8  Leu-Hb, 4  Leu-Hg,
6  CH2 (aminohexyl linker), 1  CH (aminohexyl linker), 6  CH2
(thiohexyl linker), 2 Mal-Hb), 5.40e6.33 (m, 28H, 24  H10 sugar
ring protons, 4  H5 of dC), 7.25e8.35 (m, 31H, 31  Ar-H from
dG(  8), dA(  14), dC(  4) and dT(  5)).
2.7.6. DC6 (5
0
2-Mal-[LRLRG]2-5 3
0
)
(70 nmol, yield 70%). MALDI-MS: m/z ¼ 8797 [MþH]þ
(MW ¼ 8796 calcd. for [C298H415N116O152P23S]). 1H NMR (D2O with
Y. Staroseletz et al. / Biomaterials 112 (2017) 44e6148TSP (0.01 mM), 400 MHz): d 0.70e0.99 (m, 24H, Leu-Hd), 1.25e3.25
(m, 124H, 23  H20 and 23  H200 sugar ring protons, 5  CH3 of
5  dT, 8Arg-Hb, 8  Arg-Hd, 8  Arg-Hg, 8  Leu-Hb, 4  Leu-Hg,
6  CH2 (aminohexyl linker), 1  CH (aminohexyl linker), 6  CH2
(thiohexyl linker) 2  Mal-Hb), 5.40e6.33 (m, 27H, 23  H10 sugar
ring protons, 4  H5 of dC), 7.25e8.41 (m, 30H, 30  Ar-H from
dG(  7), dA( 14), dC(  4) and dT(  5)).2.7.7. DC7 (5
0
2-Mal-[LR]4G-5 3
0
)
(72 nmol, yield 72%). MALDI-MS: m/z ¼ 8740 [MþH]þ
(MW ¼ 8739 calcd. for [C296H412N115O151P23S]). 1H NMR (D2O with
TSP (0.01 mM), 400 MHz): d 0.74e1.04 (m, 24H, Leu-Hd), 1.24e3.26
(m, 124H, 23  H20 and 23  H200 sugar ring protons, 5  CH3 of
5  dT, 8Arg-Hb, 8  Arg-Hd, 8  Arg-Hg, 8  Leu-Hb, 4  Leu-Hg,
6  CH2 (aminohexyl linker), 1  CH (aminohexyl linker), 2 Mal-
Hb), 5.59e6.40 (m, 27H, 23  H10 sugar ring protons, 4  H5 of dC),
7.38e8.41 (m, 30H, 30 Ar-H fromdG( 7), dA( 14), dC( 4) and
dT(  5)).2.7.8. DC8 (5
0
2-Mal-[LRLRG]2-6 3
0
)
(59 nmol, yield 59%). MALDI-MS: m/z ¼ 7162 [MþH]þ
(MW ¼ 7161 calcd. for [C247H353N95O120P18S]). 1H NMR (D2O with
TSP (0.01 mM), 400 MHz): d 0.76e1.02 (m, 24H, Leu-Hd), 1.22e3.20
(m, 108H, 18  H20 and 18  H200 sugar ring protons, 3  CH3 of
3  dT, 8Arg-Hb, 8  Arg-Hd, 8  Arg-Hg, 8  Leu-Hb, 4  Leu-Hg,
6  CH2 (aminohexyl linker), 1  CH (aminohexyl linker), 6  CH2
(thiohexyl linker), 2  Mal-Hb), 5.50e6.37 (m, 23H, 18  H10 sugar
ring protons, 5  H5 of dC), 7.27e8.39 (m, 25H, 25  Ar-H from
dG(  3), dA(  14), dC(  5) and dT(  3)).2.7.9. DC9 (5
0
2-Mal-[LRLRG]2e7 3
0
)
(50 nmol, yield 50%). MALDI-MS: m/z ¼ 7202 [MþH]þ
(MW ¼ 7201 calcd. for [C248H353N97O120P18S]). 1H NMR (D2O with
TSP (0.01 mM), 400 MHz): d 0.76e1.02 (m, 24H, Leu-Hd), 1.18e3.23
(m, 108H, 18  H20 and 18  H200 sugar ring protons, 3  CH3 of
3  dT, 8Arg-Hb, 8  Arg-Hd, 8  Arg-Hg, 8  Leu-Hb, 4  Leu-Hg,
6  CH2 (aminohexyl linker), 1  CH (aminohexyl linker), 6  CH2
(thiohexyl linker), 2 Mal-Hb), 5.45e6.35 (m, 22H, 18  H10 sugar
ring protons, 4  H5 of dC), 7.28e8.41 (m, 25H, 25  Ar-H from
dG(  4), dA(  14), dC(  4) and dT(  3)).2.7.10. DC10 (5
0
2-Mal-[LRLRG]2-8 3
0
)
(59 nmol, yield 59%). MALDI-MS: m/z ¼ 8757 [MþH]þ
(MW ¼ 8756 calcd. for [C297H415N114O152P23S]). 1H NMR (D2O with
TSP (0.01 mM), 400 MHz): d 0.76e0.97 (m, 24H, Leu-Hd), 1.20e3.20
(m, 124H, 23  H20 and 23  H200 sugar ring protons, 5  CH3 of
5  dT, 8Arg-Hb, 8  Arg-Hd, 8  Arg-Hg, 8  Leu-Hb, 4  Leu-Hg,
6  CH2 (aminohexyl linker), 1  CH (aminohexyl linker), 6  CH2
(thiohexyl linker), 2 Mal-Hb), 5.36e6.30 (m, 28H, 23  H10 sugar
ring protons, 5  H5 of dC), 7.14e8.39 (m, 30H, 30  Ar-H from
dG(  6), dA(  14), dC(  5) and dT(  5)).2.7.11. DC11 (5
0
2-Mal-[LRLRG]2-9 3
0
)
(62 nmol, yield 62%). MALDI-MS: m/z ¼ 8829 [MþH]þ
(MW ¼ 8828 calcd. for [C298H415N116O154P23S]). 1H NMR (D2O with
TSP (0.01 mM), 400 MHz): d 0.71e1.01 (m, 24H, Leu-Hd), 1.20e3.20
(m, 124H, 23  H20 and 23  H200 sugar ring protons, 5  CH3 of
5  dT, 8Arg-Hb, 8  Arg-Hd, 8  Arg-Hg, 8  Leu-Hb, 4  Leu-Hg,
6  CH2 (aminohexyl linker), 1  CH (aminohexyl linker), 6  CH2
(thiohexyl linker), 2 Mal-Hb), 5.39e6.33 (m, 27H, 23  H10 sugar
ring protons, 4  H5 of dC), 7.24e8.32 (m, 28H, 28  Ar-H from
dG(  9), dA(  10), dC(  4) and dT(  5)).2.8. Preparation of linearized plasmids and in vitro RNA transcripts
The detailed protocols for preparation of linearized plasmids
p67YF0 and pHIV-2 as well as in vitro transcript of yeast tRNAPhe
and 96-nts fragment of HIV-RNA (96-HIV-RNA) were reported
earlier [30]. 30-end labeling of RNA transcript with ﬂuorescein
isothiocyanate (FITC) was carried out using our previously pub-
lished method [30].
2.9. Hybridization and cleavage of 30-FITC tRNAPhe with DCs
The hybridization assays between 30-FITC-tRNAPhe and one of
the DCs, as well as subsequent quantitative data analysis were
carried out as described earlier in Ref. [30].
Cleavage experiments were carried out for 30-FITC labelled
tRNAPhe (or 96-HIV-RNA) at concentration 1 mM (single turnover
conditions) or 20 mM (multiple turnover conditions) plus one of the
DCs at concentration 20 mM (single turnover conditions) or 10 mM
(multiple turnover conditions) in 50 mM TriseHCl pH 7.0, 0.2 M
KCl, 1 mM EDTA in accordance with the previously reported pro-
tocol [30].
2.10. Molecular dynamics simulations
The MOE modelling package [35] was used to construct an
[LRLRG]2 peptide with attached linkers (i.e., N-maleoyl-b-alanine,
thiohexyl and aminohexyl groups) which were capped with
phosphate groups simulating the attachment to
oligodeoxyribonucleotides.
The system was built using the GAFF [36] and ff99SB [37] force
ﬁelds for the linkers and peptide moieties respectively. Partial
charges for the linkers were obtained using the R.E.D [38e40]
server and AMBER12's resp module [41] via the RESP method [39]
at the HF/6-31G* level of theory.
The molecular dynamics (MD) simulations were carried out
using AMBER12's pmemd module [41] in ﬁve stages: (i) a 50 000
step minimization (steepest descent algorithm for the ﬁrst 25 000
steps, conjugate gradient for the next 25 000); (ii) a 500 ps MD
simulation in which the systemwas heated linearly from 0 K to the
target temperature of 310 K; (iii) a 1 ns equilibration simulation at
310 K; (iv) a 1 ns simulation where a 20 kcal mol1 Å2 harmonic
distance restraint of 20.6 Å between the two end phosphorus atoms
(simulating their likely distance when bound to tRNAPhe) was
slowly applied over 500 ps and then further equilibrated for
another 500 ps; (v) a 10 ns production simulationwith the distance
restraint applied, sampling every 2 ps. The Generalized Born im-
plicit solvation model with no cutoff [42e44] was used for all MD
simulations. MD simulations used a time step of 2 fs and the SHAKE
algorithm [45] was applied to constrain bonds involving hydrogens.
The temperature was controlled using the Langevin thermostat
with a collision frequency of 1 ps1 [46].
2.11. Data processing and analysis
All hybridization and cleavage experiments were repeated 4e6
times independently. Experimental errors in measuring band in-
tensities by Molecular Imager FX (Bio-Rad, USA) followed by gel
images processing with GelPro Analyzer software did not exceed
5e7%. This was the estimated accuracy of cleavage data measure-
ments. OriginPro 8.0 was used for data processing, and the binding
constants Ka were evaluated using equation Ka ¼ a/([DC](1-a)),
where a is the binding extent and [DC] is the conjugate concen-
tration. Ka values were expressed as mean ± SD (standard
deviation).
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3.1. Design strategy
The overall design concept of the ‘dual’ peptidyl-oligonucleotide
conjugates is shown schematically in Fig. 1AeB. The detailed sec-
ondary structure of tRNAPhe (in-vitro transcript) along with the
binding regions for DCs and induced cleavage sites are illustrated in
Fig. 1C. The key structural elements of the ‘dual’ peptidyl-
oligonucleotide conjugates introduced here consist of two oligo-
nucleotide recognition motifs connected by amphiphilic peptide
(see Fig. 2), which acts both as a linker between two targeting ol-
igonucleotides and as the catalytic moiety to promote hydrolytic
cleavage of RNA at the adjacent sequence.
The isolated antisense recognition motifs do not contain a suf-
ﬁcient stretch of nucleotide residues to disrupt the native, ther-
modynamically stable tRNAPhe secondary structure [47e49].
However, when conjugated via a linker (Fig. 1A, dotted lines), these
dual recognition motifs are expected to enhance considerably the
likelihood of tRNAPhe:DC heteroduplex formation, becausemultiple
tRNAPhe structural elements are simultaneously disturbed. The
recognition oligonucleotide elements were designed here in such a
way as to allow a short region (3 to 5 nucleotides) of single-
stranded RNA (Fig. 1C) to remain in-between the hybridised RNA
regions, thus leaving it susceptible to cleavage by the catalytic
linker-peptide. An additional potential advantage of such a design
could be that cleavage of the target tRNAPhe sequence at this
location may potentially lead to catalytic turnover of the RNA
substrate, as the binding weakens following cleavage. The number
ofWatson-Crick base pairs involved in the resulting heteroduplexes
will be approximately halved after each successful cleavage event,
thus weakening the hybridised complex. In this work, we aimed to
investigate whether DC molecules can be released from their
complex with tRNA following cleavage and attack the next RNA
target sequence to be able to ‘cleave and leave’ again (Fig. 1A).
The synthesis of such constructs (see Tables 1 and 2 for oligo-
nucleotide and peptide sequences, DC composition and nomen-
clature) was carried out using three consecutive steps. The catalytic
peptides were synthesized using solid-phase peptide synthesis as
previously described in Ref. [30]. The conjugation of the catalytic
peptide to two oligonucleotide recognition motifs was carried out
in solution in two subsequent stages, ﬁrst via the N- and then via
the C-terminus.
The core peptide sequences chosen for incorporation into DCs
(i.e., [LR]4G, Mal-[LR]4G and Mal-[LRLRG]2; see Fig. 2C) were based
upon the RNA cleaving peptides [LR]4G-CONH2 and [LRLRG]2CONH2
that successfully demonstrated efﬁcient cleavage of yeast tRNAPhe,
when covalently attached to a single 17-mer TJC targeting oligo-
nucleotide (pGATCGAACACAGGACCT) [30]. An additional glycine
residue in the middle of the peptide chain of Mal-[LRLRG]2 was
incorporated, in an attempt to introduce additional ﬂexibility be-
tween the two recognition sequences A and B, in order to improve
the microenvironment for RNA cleavage, which can only occur via
the ‘in-line’ mechanism [33,50e53]. Furthermore, incorporation of
two additional linkers (i.e., N-maleoyl-b-alanine and thiohexyl
groups) into the structure of Mal-[LR]4G and Mal-[LRLRG]2 allowed
us to enhance further the conformational freedom of the catalytic
peptidewithin the hybridised hybrid. Arginine-containing peptides
are well known to bind to the phosphodiester backbone of RNA
through their guanidinium functionality, which carries a positive
charge at physiological pH. Furthermore, arginine residues are
common in the active sites of several ribonuclease enzymes, where
their role has been associated with the stabilisation of the phos-
phorane transition state via electrostatic interactions [54e56],
which assist the delivery of the negatively-charged 20-oxygen to thephosphorus, as well as acting as general-acid catalysts [57].
In order to investigate the effect of peptide length on RNA
cleavage activity, in addition to the core peptide [LR]4G, we also
synthesized two analogous shorter peptides, [LR]2G and [LR]3G,
which contained fewer repeats of the leucine-arginine building
block. The rationale behind this design was that a shorter peptide
regionmay force the RNA to adopt a conformationally-strained, less
thermodynamically stable DC:RNA hybridised complex, which
could potentially promote DC dissociation and improve catalytic
turnover. The catalytic peptides used in this research are listed in
Table 2, along with the nomenclature of the corresponding DCs.
The oligonucleotides incorporated into the DCs were chosen
based on their ability to hybridize with the tRNAPhe TJC loop re-
gion or 30-aminoacceptor stem (see red and blue ribbons, respec-
tively, in Fig. 1C). In addition to modifying the peptide length
between the core oligonucleotides GATCGAACACAG (within 1 or 2)
and TGGTGCGAATT (within 5), additional oligonucleotides were
designed to form single-stranded target regions of different size (5-
, 4- or 3-nt) in the target tRNAPhe region (C61-G65), which may
hypothetically affect the efﬁciency of the RNA strand cleavage (see
Tables 1 and 2 for nomenclature). This was achieved by increasing
the length of the recognition motif A (oligonucleotide 1, Table 1)
attached at the peptide N-terminus by one (GGATCGAACACAG/3)
and two (TGGATCGAACACAG/4) nucleotide residues (underlined in
the text and in Table 1). Therefore, upon DC:tRNA hybridization
with these elongated recognition motifs, the number of unhybri-
dised tRNA nucleotides in the target region (C61-G65) would be
reduced from 5 to 4 and to 3, respectively. Previously, single-
stranded target regions between 3 and 5 nucleoside residues
have promoted hydrolytic RNA cleavage [58,59] presumably due to
their ability to adopt the required ‘in-line’ geometry.
One of the fundamental problems with previous generations of
POCs is their inability to leave their RNA target, following phos-
phodiester cleavage, in order for multiple catalytic events to occur.
Therefore, it was important for us to test the hypothesis as to
whether post-cleavage dissociation would be facilitated by
replacement of the core oligonucleotide sequence 5 with a shorter
recognition motif (i.e. CGAATT/7; Table 2) at the peptide C-termi-
nus, or by incorporation of base mismatches into this shortened
recognition motif (i.e. CTAACT/6). Interestingly, the CTAACT motif,
which was previously incorporated into a peptidyl-oligonucleotide
conjugate, has been shown to display high levels of cleavage ac-
tivity of such a POC against a HIV-1 RNA transcript with notable
catalytic turnover [60,61]. To test this hypothesis, we aimed to
assess the hybridization and cleavage performance of these short-
ened DC8 and DC9 conjugates.
Finally, as a compromise between the two hybridization ex-
tremes, two longer 11-mer oligonucleotides were also designed,
one contained base mismatches (i.e. TGGTGCTAACT/8), and another
formed G-U ‘wobble’ base pairs on hybridization with tRNAPhe
(i.e.TGGTGCGGGTT/9).
3.2. Synthesis of DCs
Peptides were synthesized by manual solid phase synthesis
using the established Fmoc/tBu protocol. Peptides Mal-[LR]4G and
Mal-[LRLRG]2 were subject to an additional coupling procedure
with N-maleoyl-b-alanine to allow subsequent modiﬁcation with a
thiol-bearing group. To allow for N- and C-terminal modiﬁcations
after solid-phase synthesis of the peptides, both termini were left
unprotected as an amine (or N-Maleoyl-b-alanine) and carboxylic
acid, respectively.
DCs were synthesized by two different methods, which were
selected based upon 30- and 50-terminal oligonucleotide modiﬁca-
tions.Method 1 (see Scheme S1, ‘Supplementary Data’ and Fig. 2A)
Fig. 2. General structures of dual conjugates DC1-DC3 (A) and DC4-DC11 (B) showing the conjugation regions between the catalytic peptide (green) and two ﬂanking oligonu-
cleotide recognition motifs A (red) and B (blue) along with their 50- or 30- modiﬁcations. (C). Chemical structures and nomenclature of peptides used in the synthesis of dual
conjugates DC1 - DC11. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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oligonucleotide and a peptide N-terminal amine [62]. The second
oligonucleotide bearing a 30- aminohexyl group was then attached
via an amide bond-forming reaction at the peptide C-terminus (see
Scheme S3, ‘Supplementary Data’). Method 2 (see Scheme S2,
‘Supplementary Data’ and Fig. 2B) utilized a thiol-maleimide
‘click’ reaction between a 50-thiol modiﬁed oligonucleotide and a
N-Maleoyl-b-alanine residue at the peptide N-terminus [63]. Thesecond oligonucleotide was then attached using identical condi-
tions to Method 1.
In Method 1 (peptides [LR]2G, [LR]3G, [LR]4G), the formation of
the phosphoramidate bond between the 50 terminal phosphate of
the oligonucleotide (1) and the peptide N-terminus was achieved
using the established method of Zarytova et al. [62], with appro-
priate adjustments due to the presence of a free C-terminal car-
boxylic acid. This required use of a DMSO-soluble
Table 1
Sequences, RNA binding site and nomenclature of recognition motifs.
Recognition Motif Oligonucleotide Sequence 50/30 Length, nts Binding site
A 1 GATCGAACACAG a 12 49e60
A 2 GATCGAACACAG b 12 49e60
A 3 GGATCGAACACAG b 13 49e61
A 4 TGGATCGAACACAG b 14 49e62
B 5 TGGTGCGAATT c 11 66e76
B 6 CTAACT c,d 6 66e71
B 7 CGAATT c 6 66e71
B 8 TGGTGCTAACT c,d 11 66e76
B 9 TGGTGCGGGTT c,d 11 66e76
a 50-terminal phosphate group at the 50-end.
b Thiol-modiﬁcation at the 50-end.
c Aminohexyl linker at the 30-end.
d Mismatches are marked in bold italics.
Table 2
Dual conjugate composition and nomenclature along with association constants (Ka) and total extent of tRNAPhe cleavage.
POC Peptide Oligo within recognition Motif A Oligo within recognition Motif B Target region length Kaa, 106 M1 Cleavage extentb,%
DC1 [LR]2G 1 5 5-nt 0.95 ± 1.1 0
DC2 [LR]3G 1 5 5-nt 0.91 ± 0.9 0
DC3 [LR]4G 1 5 5-nt 0.57 ± 0.4 0
DC4 Mal-[LRLRG]2 4 5 3-nt 1.61 ± 0.2 <1d
DC5 Mal-[LRLRG]2 3 5 4-nt 1.36 ± 0.2 <1d
DC6 Mal-[LRLRG]2 2 5 5-nt 0.68 ± 0.1 100
DC7 Mal-[LR]4G 2 5 5-nt 0.55 ± 0.1 40
DC8 Mal-[LRLRG]2 2 6 5-nt Negligible binding c <1d
DC9 Mal-[LRLRG]2 2 7 5-nt Negligible binding c <1d
DC10 Mal-[LRLRG]2 2 8 5-nt Negligible binding c <1d
DC11 Mal-[LRLRG]2 2 9 5-nt Negligible binding c <1d
a Ka was evaluated using equation Ka ¼ a/[DC](1-a), where a is the binding extent and [DC] is the conjugate concentration.
b Cleavage extent was determined as a ratio of ﬂuorescence intensity measured in the RNA fragment(s) to the total ﬂuorescence intensity applied onto the gel.
c Binding extent is less than 10%; Ka was estimated to be less than 1  103 M1.
d Cleavage extent did not exceed 1%.
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along with activating agents 2,20 dipyridyl disulphide, triphenyl-
phosphine and 4-(dimethylamino)pyridine. In order to prevent
peptide self-condensation, the phosphate group of the oligonu-
cleotide was ﬁrst pre-activated in anhydrous DMSO, and the acti-
vated oligonucleotide was isolated by precipitation in diethyl ether
prior to addition of the peptide directly to the activated complex.
Conjugation of oligonucleotide (1) to peptides [LR]2G, [LR]3G,
[LR]4G gave similar yields between 80 and 90%. Prior to attachment
of the second oligonucleotide motif (5) bearing a 30-aminohexyl
group, the identity and purity of the HPLC-puriﬁed ‘single’ conju-
gates were routinely conﬁrmed by 1H NMR and 31P NMR to ensure
correct product formation (see representative 1H NMR spectra
recorded for DC1 and its precursors in Fig. 3). The conjugation of
the second recognition motif B via aminohexyl linker was achieved
through the peptide C-terminal modiﬁcation, which was carried
out in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (pH 6)
with the water-soluble 1-Ethyl-3-(3-dimethylaminopropyl)carbo-
diimide (EDC) and N-hydroxy succinimide (NHS) activating agents.
Reaction yields for attachment of the second oligonucleotide motifs
to the ‘single’ peptidyl-oligonucleotide conjugates varied from 50
to 71%.
Method 2 (peptides Mal-[LR]4G and Mal-[LRLRG]2) can be car-
ried out in buffered aqueous solutions throughout [63,64]. The 50-
thiol modiﬁed oligonucleotides, supplied as protected disulphides
were ﬁrst reduced using tris(2-carboxyethyl)phosphine (TCEP) in
phosphate-buffered saline (PBS) [64]. Unlike the reducing agent
dithiothreitol (DTT), TCEP is not required to be removed from so-
lution. Following disulﬁde reduction, the pH of the solution was
raised (pH 7), and the peptide dissolved in DMSO was addeddropwise. The reaction between the 50-thiol and maleimide group
was spontaneous [65], and the product yields for all ‘single’ con-
jugates synthesized in this manner were near quantitative
(95e100%). Isolation of stereoisomers formed by this reaction was
not carried out. Prior to attachment of the second oligonucleotides
to generate DCs 4 to 11, the ‘single’ conjugates were puriﬁed by
HPLC and routinely characterized by 1H NMR to ensure correct
product formation (data not shown here). However, due to the
nature of the covalent attachment, 31P NMR spectroscopy could not
be used in this case to demonstrate attachment of the peptide to
the oligonucleotide. The conjugation of the second recognition
motif B (i.e. oligonucleotides 5, 6, 7, 8 or 9) was then achieved using
the same approach as that described above for Method 1.3.3. Characterization of DCs
The identity and purity of all ‘dual’ peptidyl-oligonucleotide
conjugates were conﬁrmed by IEX or RP-HPLC, Urea-PAGE, 31P
and/or 1H NMR spectroscopy, and mass spectrometry. Precise
analysis of 1H NMR spectra is convoluted by the many overlapping
signals in the peptide and oligonucleotide sugar ring regions
(0.5e4.7 ppm). However, through comparison of the unconjugated
oligonucleotides, intermediate ‘single’ peptidyl-oligonucleotide
conjugates and the product dual peptidyl-oligonucleotide conju-
gates, we were able to conﬁdently conﬁrm the presence of the
components and the correct ratio of oligonucleotide to peptide. As
an example, Fig. 3 shows the 1H NMR spectra of terminally-
modiﬁed oligodeoxynucleotide starting materials (1 and 5), the
intermediate peptidyl-oligonucleotide conjugation product of 1
with peptide [LR]2G, and the ﬁnal-product DC1. Following
Fig. 3. Representative 1H NMR spectra (400 MHz, Bruker Avance IIþ 400) demonstrating a generic approach for characterization of ‘single’ and ‘dual’ peptidyl-oligonucleotide
conjugates. NMR spectra of unconjugated oligonucleotides (A þ B) along with intermediate (i.e. ‘single’) peptidyl-oligonucleotide conjugate (C) and ‘dual’ peptidyl-
oligonucleotide conjugate DC1 (D). Integration of H30/H40/H50/H500 regions not carried out due to inﬂuence of water suppression.
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the resonance areas of 0.5e0.8, 3.0e3.4 and 3.6e3.7 ppm can be
assigned to Leu-Hd, Arg-Hd and Gly-Ha protons, respectively. The
considerable spectral overlap between the peptide protons and the
oligonucleotide sugar ring protons made unambiguous assignment
of the 1H NMR signals difﬁcult. However, through careful signal
integration in the aromatic (7.3e8.4 ppm) and H10/Ar-H5
(5.5e6.4 ppm) resonance areas of the oligonucleotide fragment, as
well as those generated by Leu-Hd, Arg-Hd and Gly-Ha of the pep-
tide component, it was possible to conﬁrm 1:1 stoichiometric ratio
of peptide to oligonucleotide.
Following attachment of the second oligodeoxynucleotide motif
(5), the 1H NMR spectrum of DC1 became even more complex and,
consequently, only some signals could be fully characterized using
conventional 1D NMR techniques. Again, the Leu-Hd peptide signals
were clearly observed; however, the Gly-Ha signal was shifted
downﬁeld and resided amongst the H40/H50/H500 oligonucleotide
sugar ring protons, due to the inﬂuence of the newly formed C-
terminal amide bond. Other notable additions to the 1H NMR
spectrum of DC1were the thymidine-CH3 protons ( 4) of 5, which
formed clear singlets together with the T-CH3 protons of 1. How-
ever, precise integration of these resonances was not possible due
to the interference from Arg-Hb,g, Leu-Hb,g and H2/H200 sugar ring
protons of the oligonucleotide components. Incorporation of the
second oligodeoxynucleotide motif was conﬁrmed through inte-
gration of the aromatic (7.3e8.4 ppm) and H10/Ar-H5
(5.5e6.4 ppm) regions. In the illustrated example, these showed an
additional 13 and 12 proton signals, respectively, compared to the
intermediate peptidyl-oligonucleotide conjugate (1-[LR]2G). Again
using these regions, it was possible to conﬁrm the correct stoi-
chiometric ratio (1:1) of peptide to oligonucleotide components. 1H
NMR spectra of all DCs were assigned in a similar fashion and all
agreed with theoretical predictions.
31P NMR analysis of DCs 1, 2 and 3 displayed the characteristic
deshielding (5e6 ppm) of the terminal 50-31P resonance due to
deshielding by the peptide N-terminus (see ‘Materials andMethods’). However, 31P NMR could not be used as a character-
ization tool for DCs 4 to 11 due to the nature of the 50-thiol
modiﬁcation.
In mass spectrometry analysis, DCs were identiﬁed as mono- or
di-sodium/potassium adducts with experimental masses in
agreement with theoretical calculations (see ‘Materials and
Methods’). No fragmentation of DCs was observed under the
experimental conditions used.3.4. Hybridization of DCs to tRNAPhe
Since cleavage of target RNA is expected to occur within the
complementary complex formed between tRNAPhe and conjugate,
the hybridization is an essential step preceding the RNA cleavage
event.
The ability of DCs to hybridize with their target regions was
determined by gel-shift analysis (see Fig. 4 and Table 2 for associ-
ation constants). This was carried out by incubating 30- FITC
labelled tRNAPhe in a standard buffer (see ‘Materials and Methods’)
with increasing concentrations of DCs, followed by analysis of the
reaction mixtures by native 10% PAGE. Binding of the DC to 30-FITC-
tRNAPhe resulted in the formation of heteroduplexes with reduced
electrophoretic mobility when compared to the unbound 30-FITC-
tRNAPhe. Provided that 100% binding was observed binding con-
stants could be estimated [49,51,52]. Previously, this technique has
been used to identify oligonucleotides that bind with high efﬁ-
ciency to 30-FITC-tRNAPhe, such as: (i) a single 17-mer oligonucle-
otide recognition motif (GATCGAACACAGGACCT, Ka ¼
(7.0 ± 1)  106 M1) targeting tRNAPhe residues 44e61 encom-
passing variable and TJC loops; and (ii) a 14-mer
(TGGTGCGAATTCTG) targeting the 30-ACCA overhang and
acceptor stem [30,47,49]. In both cases, a single-stranded RNA re-
gion is required to initiate oligonucleotide:tRNAPhe hybridization,
when only then can more structured RNA regions be unraveled.
With the exception of oligonucleotides 6 and 7, our oligonucleo-
tides were designed here to target the same single-stranded
Fig. 4. Gel-shift analysis of hybridization of the DC1, DC2 and DC6 with 30-FITC-tRNAPhe (1 mM). A. Representative images of the 12% PAAG showing binding of the selected dual
conjugates (DC1, DC2 and DC6) with 30-FITC-tRNAPhe. The conjugate type and concentrations are indicated at the top. Arrows show unbound 30-FITC-tRNAPhe and 30-FITC-tRNAPhe-
conjugate complex. B. Secondary plot of the data shown in A.
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our DCs here, each oligonucleotide binding motif is shorter than
those used previously (Fig. 1C). As expected, gel-shift analyses
revealed that the unmodiﬁed oligonucleotides alone did not hy-
bridize with their target RNA region under the conditions used
(data not shown here). However, when operating jointly as part of
the DC, both of these two oligonucleotide targeting motifs were
able to mutually enhance the binding afﬁnity of the conjugated
molecule and hybridize with their target. As an example, demon-
stration of hybridization for DC1, DC2, and DC6 is shown (Fig. 4).
The dual conjugates studied here can be divided into two cat-
egories with respect to their ability to hybridize tRNAPhe. Conju-
gates DC1 to DC7 from the ﬁrst category demonstrated saturation
binding to tRNAPhe (Fig. 4 and Table 2) when 100% of the tRNAPhe
became hybridised to the DCs at concentrations above 5 mM. The
association constant, Ka, calculated from this data, varied from 0.55
to 1.61  106 M1, showing that these conjugates had a strong af-
ﬁnity towards the target molecule (see Table 2). As expected, DC4,
which forms two additional base-pairs (due to the lengthening of
the Recognition Motif A by two nucleotides), exhibited the highest
Ka value (Ka ¼ 1.61  106 M1). In agreement with this, DC5 with
one nucleotide less in its sequence bound to tRNAPhe less tightly
(Ka¼ 1.36 ± 0.2 106 M1), followed by DC6with additional length
reduction by another nucleotide residue
(Ka ¼ 0.68 ± 0.2  106 M1).
Among conjugates from the ﬁrst category, which differed in the
length of the peptide joining the two recognition motifs (DC1, DC2,
DC3, DC6 and DC7) DC1, the shortest peptide displayed the highestbinding constant (see Table 2). However, this result was not
signiﬁcantly greater than those obtained for DC6 and DC7, sug-
gesting that the length and charge on the peptide (5-/7-/9-/10-/9-
mer with þ2/þ3/þ4/þ4/þ4, respectively) did not affect DC bind-
ing to a signiﬁcant extent. This is in agreement with previous re-
sults for single conjugates, suggesting that the predominant force
for hybridization is Watson and Crick base pairing and not elec-
trostatic interactions between arginine residues and the phos-
phodiester backbone. As expected, the replacement of peptideMal-
[LR]4G (DC7) with Mal-[LRLRG]2 (DC6) containing an extra glycine
residue had only a veryminor effect on the binding of the conjugate
(Table 2). Additionally, DC7, containing identical antisense motifs to
DC3, but with the replacement of a phosphoramidate linker, with a
longer and more ﬂexible thiol-maleimide linker showed no change
in its binding constant. This suggests that an increased ﬂexibility in
this case did not contribute to or affect the binding ability of the
DCs.
The second category of conjugates, which is represented by the
conjugates DC8, DC9, DC10 and DC11 with truncated and/or mis-
matched recognition motif B (oligonucleotides 6, 7, 8 and 9,
respectively) showed very poor or negligible hybridization towards
tRNAPhe over a wide range of concentrations (up to 50 mM), with
less than 10% extent of binding. Base mismatches and/or trunca-
tions of the RM B to miss out the 30 overhang seem to be detri-
mental to binding efﬁciency, which is in a good agreement with
previously obtained data [49,51,52].
Overall, binding of DC to RNA seemed to be driven solely by the
oligonucleotide recognitionmotifs, as the peptide motifs seemed to
2 Hereinafter cleavage products are labelled by the corresponding nucleotide
residue located at the 50- position from the cleavage point. For example, A64
product generated by cleavage at A64-G65 position corresponds to the 50-G65-A76-
30 RNA fragment.
Y. Staroseletz et al. / Biomaterials 112 (2017) 44e6154have negligible inﬂuence on the binding of the DCs to RNA.
3.5. Cleavage activity against of tRNAPhe
Cleavage activities of the dual conjugates DC1-DC11 were
screened at physiological pH 7.4 and temperature of 37 C against
30-FITC-tRNAPhe (containing target regions complementary to the
conjugate recognition motifs A and B) and 30-FITC-HIV-RNA (which
represents non-speciﬁc RNA target for the designed series of DCs).
Tris-buffer was used here because it does not interfere with the
RNA trans-esteriﬁcation process [59,66,67]. It was supplemented
with EDTA (1 mM) tominimise undesirable metal-ion induced RNA
cleavage. Cleavage products were analysed by PAGE and identiﬁed
by comparison with RNase T1 and imidazole tRNAPhe hydrolysis
ladders.
DC1, DC2 and DC3 appeared to be catalytically inactive towards
the target tRNAPhe sequence, possibly because the catalytic pep-
tides ([LR]2G, [LR]3G and [LR]4G, respectively) were attached to the
recognition motifs A and B (oligonucleotides 1 and 5) via a zero-
length phosphoramidate linker. This absence of catalytic activity
may stem from the lack of essential conformational freedom upon
hybridization of these conjugates to tRNAPhe. The zero-length
phosphoramidate linker at the 50-end of DC1, DC2 and DC3 may
restrict both peptide and the nucleotides, within the target site,
from forming a favourable conformation for cleavage, leading to
catalytic failure.
In order to investigate the plausibility of this hypothesis, the
remaining dual conjugates DC4 - DC11 were assessed on their
catalytic activity against tRNAPhe, which incorporated extended and
highly ﬂexible N-maleoyl-b-alanine and thiol-hexyl linkers ﬂank-
ing the N-terminus of the catalytic peptide. The enhanced degree of
conformational freedom had a considerable effect on their catalytic
performance. Some of the conjugates from this series were highly
catalytically active (Fig. 5), presumably due to increased ﬂexibility
of the heterocomplex around the target site. Indeed, conjugate DC7
induced 40% total cleavage of tRNAPhe upon 24h incubation under
identical conditions (cf. 0% RNA cleavage for DC1 - DC5; Table 2).
Furthermore, incorporation of an extra glycine residue into the
catalytic peptideMal-[LRLRG]2 of DC6 promoted RNA cleavage even
further and allowed this conjugate to achieve maximal catalytic
activity (i.e., 100%) in a much shorter incubation time (i.e., 4h). The
representative images of electrophoretic analysis of 30-FITC-tRNA-
Phe cleavage products are shown (Fig. 5) for DC6, DC7 and DC8
conjugates, and data summarised in Table 2.
The key role of conformational freedom in the catalytic cleavage
of RNA by this class of dual conjugates was further conﬁrmed by the
reduced activity of two other conjugates (i.e., DC5 and DC4) that
contain the elongated recognition motif A, with 1 and 2 extra nu-
cleotides, respectively, thus reducing the size of the RNA single-
stranded target region. Indeed, narrowing the gap between the
recognition motifs A and B within the complementary complex
with tRNAPhe led to a complete loss of the cleavage activity seen for
these conjugates, presumably due to the conformational con-
straints, induced in the vicinity of the catalytic peptide.
However, our attempts to provide an even higher degree of
freedom for the remaining dual conjugates (DC8, DC9, DC10 and
DC12), to allow them to ‘cleave and leave’ the hybridised complex,
appeared to be detrimental for their catalytic performance (see
Table 2). Indeed, these conjugates, which incorporated either
shortened and/or mismatched recognition motif B (oligonucleo-
tides 6, 7, 8 and 9, respectively) showed negligible levels of binding
afﬁnity towards tRNAPhe with an estimated Ka of less than
1  103 M1, with consequently poor catalytic activity (less than
1%). Clearly, the success of sequence-speciﬁc RNA cleavage relies on
a very ﬁne mechanistic balance between conformational tuningand base pair matching. Cleavage may be drastically suppressed by
extremes, that is, by the lack of sufﬁcient conformational freedom
or by a disproportionate excess of it. This may be avoided, though,
by careful structural consideration and rational structure-based
design of the conjugates using, for example, multi-dimensional
NMR spectroscopy and/or high level computational approaches.3.6. Cleavage proﬁles and dynamics of tRNAPhe cleavage induced by
DC6 and DC7
The kinetics of tRNAPhe cleavage induced by themost active dual
conjugates (i.e., DC6 and DC7) was evaluated from the time course
of the cleavage reaction by measuring the extent of total tRNA
cleavage against the incubation time (see Fig. 5). The kinetic curve
for DC7 had a tendency to reach a plateau over a 24 h time period,
which corresponded to 40% of overall tRNAPhe cleavage. However,
in the case of the DC6 conjugate, the plateau values reached 100% of
total tRNAPhe cleavage, with a complete disappearance of the intact
tRNAPhe band (Fig. 5A). Moreover, the kinetic curves measured for
this dual conjugate reached a plateau in a much shorter period (i.e.,
within 4 h), and further incubation (up to 8 h) led to a partial
disappearance of the longer cleavage products, accompanied by
accumulation of shorter RNA fragments.
Careful analysis of the tRNAPhe cleavage sites identiﬁed for the
most active conjugates DC7 and DC6 (see Fig. S4 and S5 in the
‘Supplementary Data’) revealed that even minor structural alter-
ations in the peptide sequence (i.e., an extra glycine residue in the
Mal-[LRLRG]2 present in the DC6 conjugate) could lead to a dra-
matic change in the RNA cleavage proﬁle. Indeed, conjugate DC7
showed its ability to cleave tRNAPhe both within the target region
61CACAG65 (mainly at A62-C63 position) and outside this region at
two Pyr-X sites (U9-A10 and C25-G26) (see Fig. 5A and Fig. S4). All
identiﬁed sites induced by DC7 were recognized as primary
cleavage sites, since the amounts of cleavage products2 increase
gradually over 24 h without any noticeable changes in the cleavage
patterns.
Conjugate DC6 showed signiﬁcantly more complicated and
diverse cleavage patterns (see Fig. 5A and Fig. S5). One of the most
interesting features of the DC6 conjugate seems to be its remark-
able difference in base-selectivity of RNA cleavage seen for the
target site against that observed for the distantly located regions.
Indeed, at the target region 61CACAG65 of the 30-FITC-tRNAPhe, DC6
attacked predominantly the A64-G65 position (60% over 24 h), with
relatively slow cleavage kinetics, which reached a plateau only after
8 h of incubation. This was followed by a gradual accumulation of
the minor products generated by cleavage at C63-А64 and A62-C63
sites (10% and 1%, respectively), which showed even slower cleav-
age kinetics. In contrast, outside the target region, DC6 exhibited
predominately GeX cleavage speciﬁcity, thus mimicking T1-
ribonuclease activity (see Fig. 1C for location of cleavage sites).
A pictorial description of the tRNAPhe cleavage products induced
by DC6 (A) along with a quantitative analysis of their accumulation
over 24 h (B) is given in Fig. S5. In general, DC6 showed a ‘natural’
preference to cleave G-X phosphodiester bonds. However, when it
became strongly bound to tRNA next to a single-stranded RNA re-
gion of 5 or more nucleotide residues, it tended to cleave any other
linkages located in its close proximity (for example, A64-G65 and
C63-A64).
Outside the targeted site, DC6 cleaved a number of G-X linkages
Fig. 5. Time courses of the cleavage reaction of 30-FITC-tRNAPhe with dual peptidyl-oligonucleotide conjugates (DC6, DC7 and DC8). A. Representative images of 12% PAAM/8 M urea
gel after electrophoresis of 30-FITC-tRNAPhe cleavage products as a function of the incubation time. Lanes T1 and Im, partial 30-FITC-tRNAPhe digestion with RNase T1 and imidazole,
respectively. Lane C, 30-FITC-tRNAPhe was incubated without conjugates for 24 h. 30-FITC-tRNAPhe (1 mM) was incubated with the conjugates (20 mM) at 37 C for different time
periods. Positions of RNA cleavage by RNase T1 and conjugates are shown on left and right respectively. B. Secondary plot of the data shown in A showing the total cleavage extent
(%) plotted against the incubation time.
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A35  G45-U47. Cleavage at all other G-X sites was found to be
insigniﬁcant (1%). The G20-A21 bond appears to be the most
sensitive towards cleavage by the DC6 conjugate, as thecorresponding cleavage product started to become detectable
almost immediately (i.e., after 25 min incubation with the conju-
gate). Cleavage at the G20-A21 site may be the consequence of the
two main events.
Y. Staroseletz et al. / Biomaterials 112 (2017) 44e6156(i) The hybridization of DC6 with tRNA may cause a destruction
of the previously stable tertiary (L-form) tRNA molecule,
which is accompanied by unfolding of the acceptor stem and
T-stem [68]. This would facilitate the formation of the
extended, gap-containing duplex and trigger the entire
structural re-arrangement in the junction area, thus leading
to increased ﬂexibility of the D-stem and D-loop as well as
the anticodon loop. The overall conformational ﬂexibility of
the entire tRNA structure seems to facilitate the interactions
of the catalytic peptides with previously distant (in the intact
L-form) regions of tRNA.
(ii) As a result of this enhanced structural ﬂexibility, the G20-A21
bond appears to become the most favourable point to
accommodate the ‘in-line ‘conformation, which is crucial for
cleavage.
The cleavage of the other G-X bonds outside the target region
(i.e., G34-A35, G42-G43, G43-A44 and G45-G46 and G46-U47) may
be governed mainly by their structural accessibility and occasional
opportunities to approach the peptide during some random
conformational ﬂuctuations. The ability of these sites to adopt the
‘in-line’ conformations is another important factor to promote a
successful cleavage event.
Since both DC6 and DC7 conjugates show efﬁcient hybridization
with tRNAPhe (i.e., 100% at the reaction conditions) and contain
exactly the same oligonucleotide recognition motifs, the marked
differences in cleavage patterns and in the rates of RNA cleavage
can be attributed solely to the additional glycine residue in the
structure of DC6. This ﬁnding provides strong evidence that
incorporation of a single amino acid into the peptide structure may
completely switch cleavage speciﬁcity from Pyr-X to G-X. The re-
sults of this study are in agreement with the previous ﬁndings [30]
that elongation of the peptide sequence from LRLRLRLRG to
LRLRGLRLRG by insertion of only one extra amino acid in the
middle of the peptide chain led to a dramatic increase in cleavage
activity (from 24 ± 3% to 97± 8%). This discovery might be attrib-
uted to the gain in conformational freedom from the additional
glycine residue, thus allowing the recognition motifs to optimise
interactions with the target RNA sequence. It is well recognized that
glycine residues play a crucial role in the active sites of many en-
zymes, as they provide a degree of conformational freedom to
accommodate substrate binding and catalysis [69e72].
3.7. Evaluation of distances between the catalytic peptide and the
main cleavage sites
We evaluated distances between the bridging phosphorus
atoms of the C60-p-C61 site, which correspond to the region in the
TJC-arm of tRNAPhe opposite to the attachment point of the cat-
alytic peptide, and themain RNA cleavage sites induced by DC6 and
DC7 (Fig. 6 (A) and (B), respectively) using an available crystallo-
graphic structure of a yeast tRNAPhe [73] and the MOE software
[35].
For the DC6:tRNAPhe complex, the distances to the main cleav-
age points vary (Table S1 in the ‘Supplementary data’) from 12.2 Å
(C60-G18) to 54 Å (C60-G34). For the DC7:tRNAPhe complex, the
distances to the main cleavage sites do not exceed 33 Å.
The longest distance between the phosphate atoms (i.e. points of
attachment) and the guanidinium group nitrogen of one of the four
arginine residues can be considered as an action radius for the
catalytic peptide. Although approximate, the restraint biased MD
simulations give us an indication that the peptide can potentially
adopt some conformations where this distance could reach up to
36 Å. It is noted that this preliminary simulation model does not
take into account the impact of the tRNA topology nor the effect ofionic interactions on the conformational ﬂexibility of the peptide,
however it does give us a basic estimate of its probable behaviour.
Fig. 6 (C) demonstrates representative conformations of the
peptide which, if adopted, would allow almost all cleavage sites to
be reached. Based on these evaluations, we can conclude that only
one region (G34-A35) out of 9 main cleavage sites seems to be
beyond the ‘action radius’ of the conjugate, as the distance was
found to be 54 Å between this site and the bridging phosphorus
atoms of the C60-p-C61 region within the intact tRNAPhe structure.
tRNAPhe is known to have signiﬁcant conformational ﬂexibility
[74e76], which may allow considerable structural ﬂuctuations due
to the absence of the modiﬁed nucleotides in transcript tRNAPhe, a
lack of Mg2þ ions in the reaction mixture and some other factors
that may signiﬁcantly enhance the conformational freedom of
tRNAPhe. For example, as discussed earlier, binding of DC6 to
tRNAPhe triggers unfolding of the TJC-arm and amino acceptor
stem, thus making the whole structure even more ﬂexible and
accessible for cleavage. The other major cleavage sites (G18-G19,
G19-G20, G20-A21, G45-G46, G46-U47) seem to be located within
this ‘reactive radius’, as the distance between these sites and the
points of attachment of the peptide does not exceed 25.4 Å.
Possible mechanisms of tRNA cleavage induced by this type of
bioconjugate were discussed previously [30,32,33,57] with a
comprehensive coverage of both general acid-base catalysis via
phosphodiester transesteriﬁcation and guanidinium-mediated RNA
cleavage.
A new attempt to further investigate the catalytic role of gua-
nidinium groups in promoting transesteriﬁcation was recently
made [56]. The study shows that the hydrolysis of phosphodiester
bonds is catalysed by synchronized action of two guanidine groups
present in the same molecular structure. It has been shown that
bifunctional chemical nucleases built upon diphenylmethane ana-
logues bearing two di-guanidine functional groups were capable of
cleaving 2-hydroxypropyl-p-nitrophenyl phosphate (an RNA
mimic) via an acid-base mechanism, similar to that seen for RNase
A. This catalysis was achieved by a cooperative proton transfer
between the neutral guanidine group (general base) and proton-
ated guanidinium residue (general acid). Interestingly, the func-
tional properties of the guanidinium moiety associated with the
positive charge were shown to play a dual role in catalysis by (i)
coordinating the negatively charged phosphate group through an
electrostatic interaction and (ii) acting as an electrophilic activator
and hence, enhancing the transesteriﬁcation reaction. The struc-
tural properties of the molecular scaffold between the guanidine
residues played a crucial role in the catalytic cleavage of the RNA
analogues. The success of the phosphodiester cleavage seemed to
depend on a compromise between spatial separation of the gua-
nidine groups, structural pre-organisation and ﬂexibility. Molecular
ﬂexibility was shown to be an important factor in catalysis, pre-
sumably, due to a high increase in conformational freedom, which
may allow the bifunctional catalyst to adapt to the substrate in the
transition state. However, the accompanying entropic cost might be
detrimental for the catalytic efﬁciency. Although generally valu-
able, these mechanistic studies [56], which were carried out in a
mixture of organic solvents, can only be tentatively compared to
the cleavage experiments performed against biologically relevant
RNA in purely aqueous solutions at physiological pH values.
Furthermore, the question concerning the ﬁne base-speciﬁc mech-
anisms of RNA cleavage induced by the DCs remains unanswered.
3.8. Concentration dependences of tRNAPhe cleavage by DC6 and
DC7
Since the conjugate DC6 (or DC7) was present in a 20-fold excess
against tRNAPhe (i.e., 20 mMDC6 against 1 mM tRNAPhe), it remained
Y. Staroseletz et al. / Biomaterials 112 (2017) 44e61 57unclear how many molecules of DC6 (or DC7) may potentially
participate in the cleavage of each tRNAPhe molecule. Although the
conjugates were designed to bind tRNAPhe at 1:1 molar ratio, we
cannot completely exclude the possibility of cooperative contri-
bution of the additional conjugate molecules in RNA cleavage. Such
formation of multimolecular complexes between RNA and chemi-
cal ribonucleases preceding the cleavage event has been experi-
mentally demonstrated [77]. In order to investigate the mechanism
of the tRNAPhe cleavage process, by the most active conjugates DC6
and DC7, we studied the cleavage proﬁles at their different con-
centrations. For DC6, we also looked at the cleavage kinetics in a 2-
fold excess of tRNA (20 mM) over DC6 (10 mM).
The concentration dependences of tRNAPhe cleavage by both
DC6 and DC7 conjugates exhibited sigmoidal behaviour, with a
considerable lag period (Fig. 7) until the conjugate concentration
reached 5 mM in the case of DC6, or until the concentration
exceeded 10 mM for DC7. In contrast, the concentration dependence
of binding to tRNA (Fig. 7B, dotted curves), estimated for both DC6
and DC7 conjugates, showed the usual hyperbolic character with
curves reaching a plateau at around 7 mM in both cases.
The sigmoidal character of the cleavage curves and the presence
of the lag period of the binding curves are consistent with some
positive cooperativity taking place during the site-selective tRNA
cleavage. This indicates that the complex formation might occur
through several consecutive steps, similar to a process seen earlier
for some oligonucleotides targeting the TJC-loop [46].
There are at least two possible scenarios involving a cascade of
subsequent events, which may explain (to a certain extent) the
observed lag periods in the RNA cleavage by this class of conjugates.
First, the conjugate may exist in solution as an ensemble of various
conformational forms, and only when the effective concentration of
the catalytically-active conformation of DC6 (or DC7) is achieved in
the reaction mixture, does the RNA cleavage becomes detectable.
This scenario assumes a quasi-stable complex within the associa-
tion-dissociation process. It is based on a hypothesis that RNA
cleavage can occur only within the ‘productive’ complex generated
by the conjugate in its catalytically active form, which ultimately
leads to a transformation of tRNA to its cleavage products. Another
possible scenario may involve simultaneous interactions of two or
more conjugate molecules with the same tRNA sequence, thus
leading to formation of a ‘reactive conformation’. According to this
hypothesis, the ﬁrst conjugate molecule is hybridised with the
complementary sequence of the RNA target, whereas the second
conjugate molecule or several molecular species are somehow
involved in the catalysis through the formation of the ‘productive’
complex.
Both proposed scenarios could offer an explanation for the
observed lag of cleavage against the binding curve (see Fig. 7).
According to the ﬁrst scenario, the effective cleavage of RNA is not
seen in the conditions when the effective concentration of an
‘active conformation’ of DC6 (or DC7) is not sufﬁcient for the
cleavage to be detectable. According to the second scenario, theFig. 6. Structural evaluation of accessibility of the main cleavage sites by the catalytic
peptide seen for the DC6:tRNAPhe andDC7:tRNAPhe complexes. Nucleotide residues from
the C60-p-C61 region of the tRNAPhe are indicated in cyan. (A). Cleavage sites outside the
target regionwithin the DC6:tRNAPhe complex are shown in blue, green, yellow and red
for the G3-G26, G30-37, G42-G46 and G71 clusters, respectively. (B) Cleavage sites
outside the target regionwithin the DC7:tRNAPhe complex are shown in blue, green and
red for thenucleotide residuesU8, C25andA62, respectively. (C) Representative example
conformations of the Mal-[LRLRG]2 peptide generated via the MD simulations demon-
strating the longest distance (thick dashed arrow) achieved between the phosphate
atoms (i.e. points of attachment) and the guanidinium group nitrogen of one of the four
arginine residues. The distance between the points of the peptide attachmentwithin the
hybridised complexes is indicated by the dotted arrow.
Fig. 7. Cleavage of 30-FITC-tRNAPhe with dual peptidyl-oligonucleotide conjugates DC6 and DC7 as a function of conjugate concentrations. A. Representative images of 12% PAAM/
8 M urea gel after electrophoresis of 30-FITC-tRNAPhe cleavage products. Lanes T1 and Im, partial RNA digestion with RNase T1 and imidazole, respectively. 30-FITC-tRNAPhe (1 mM)
was incubated with conjugates at various concentrations at 37 C for 24 h. Positions of RNA cleavage by RNase T1 and conjugates are shown on left and right respectively. B.
Concentration dependences of 30-FITC-tRNAPhe cleavage (solid lines) and binding (dotted lines) of 30-FITC-tRNAPhe with DC6 (squares) and DC7 (triangles) at 37 C.
Y. Staroseletz et al. / Biomaterials 112 (2017) 44e6158described mechanism can be activated after the conjugate con-
centration reaches ‘critical’ concentrations (i.e., 5 and 10 mM for DC6
and DC7, respectively, in this example) needed for cooperative
action.
The suggested hypotheses are also in agreement with our
experimental data that neither DC6 nor DC7 cleave non-complementary RNA sequences and show absolute sequence-
speciﬁcity (see Fig. S6, ‘Supplementary Data’). 30-FITC labelled 96-
HIV-RNA (96-nts fragment of HIV-RNA, prepared by in vitro tran-
scription) does not have any essential homology with yeast tRNA-
Phe, and was used here to evaluate the cleavage selectivity of DC6
and DC7 conjugates. Upon incubation of 30-FITC-96-HIV-RNA
Fig. 8. Kinetics of 30-FITC-tRNAPhe cleavage with DC6 A in excess of DC6 (20 mM DC6, 1 mM 30-FITC-tRNAPhe) and B in excess of 30-FITC-tRNAPhe (10 mM DC6, 20 mM 30-FITC-tRNAPhe).
Representative images of 12% PAAM/8 M urea gel after electrophoresis of 30-FITC-tRNAPhe cleavage products. Lanes T1 and Im, partial RNA digestion with RNase T1 and imidazole,
respectively. Lane C, 30-FITC-tRNAPhe incubated in the absence of conjugate for 24 h. 30-FITC-tRNAPhe was incubated with DC6 at 37 C. Positions of RNA cleavage RNase T1 are shown
on the left.
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cleavage being observed during 24 h incubation at 37 C (Fig. S6).
These results conﬁrmed that (i) the designed dual conjugates work
only as sequence-selective artiﬁcial ribonuclease and (ii) all cleav-
age events observed during the incubation of tRNAPhe with DC6 or
DC7 can occur only within the complementary complex between
tRNAPhe and dual conjugate.3.9. Cleavage of tRNAPhe in excess with respect to DC6
To explore further a plausible mechanism of RNA cleavage, we
carried out the reaction in a 2-fold excess of tRNAPhe (20 mM) with
respect to DC6 (10 mM; Fig. 8). 50% of the tRNAPhe cleavage was
achieved in 24 h, and further incubation of tRNAPhe in the presence
of DC6 over next 72 h changed neither the overall extent of
cleavage, nor the cleavage patterns (Fig. 8B).
Furthermore, the qualitative and quantitative distribution of the
tRNAPhe cleavage products were very similar to those seen for the
4 h reaction period when 20-fold excess of the conjugate was used
(cf. tRNAPhe at 1 mM and DC6 at 20 mM; Fig. 8A). This excludes
neither the ﬁrst scenario (insufﬁcient concentrations of the cata-
lytically active conjugate concentration) nor the second scenario (a
necessity of multimeric catalytic complexes).
Although the total extent of tRNAPhe cleavage reached was only
50% in the case of a 2-fold excess of RNA over DC6, we cannot
completely exclude the possibility of the catalytic turnover of the
reaction, especially in the case of scenario 2, with more than one
conjugate molecule involved in the catalysis, and this aspect re-
quires separate further investigation.
To conclude, the perception of the role that regulatory (non-
protein coding) RNAs play in normal or pathologically compro-
mised cells [3e8] led to a recognition of RNA as one of the most
important biological targets for future therapeutic interventions. It
was demonstrated that RNAs in cells are involved in the regulationof crucial biological functions, and thus an interference with their
expression proﬁles or alteration of their speciﬁcity may play a
pivotal role in progression of many pathological conditions (e.g.
different types of cancer as well as cardiomyopathies and disorders
of the central nervous system). With this in mind, we focus our
research on development of a new generation of catalytically active
bioconjugates capable of recognizing and destroying certain regu-
latory RNAs, which may trigger the discovery of new ways of
switching intracellular signaling pathways from ‘diseased’ to
‘normal’. Although this research is only the beginning of this chal-
lenging direction, our encouraging results obtained for the pilot
model RNA systems may open new exciting avenues in the RNA
targeting and inspire others to search for novel approaches in
treatment of human pathophysiology. We anticipate that the next
challenge in this area will be (i) to investigate whether these (or
similar) catalytic bioconjugates are able to demonstrate a sufﬁcient
catalytic activity in cells and destroy cellular miRNAs in a selective
and controlled manner. In the case of success, it will be crucial to
subsequently evaluate (ii) the time-span of such induced miRNA
silencing impact and (iii) assess whether or not this effect is sufﬁ-
cient to achieve an essential alteration in gene expression proﬁle to
reach a required level of therapeutic response.4. Conclusion
A novel class of catalytic biomaterials with two oligonucleotide
recognitionmotifs conjugated to an amphipathic peptide promoted
hydrolytic cleavage of tRNAPhe at the targeted site, adjacent to the
sequence-speciﬁc hybridization. Two out of the eleven conjugates
synthesized, differing in the length and structure of peptide,
oligonucleotide recognition motifs and linkers, demonstrated high
cleavage activity against tRNAPhe and illuminated the structural
requirements of sequence-speciﬁc catalysis.
Y. Staroseletz et al. / Biomaterials 112 (2017) 44e6160(1) Highly ﬂexible (e.g. N-maleoyl-b-alanine, thiol-hexyl) linkers
between the oligonucleotide recognition motifs and the
catalytic peptide were vital, in order to provide sufﬁcient
ﬂexibility for the peptide to adopt a conformation favourable
for successful RNA cleavage.
(2) Narrowing the gap between the two recognition motifs
within the complementary complex with tRNAPhe led to a
reduced size of RNA in targeted single-stranded target re-
gion, which may result in complete loss of catalytic activity.
(3) Addition of an extra glycine residue in the peptide sequence
dramatically changed both the cleavage patterns and the
extent of RNA cleavage.
(4) The success of sequence-speciﬁc RNA cleavage depended
upon a ﬁne mechanistic balance between conformational
tuning and base pair matching in order to achieve the
remarkably high RNA cleavage activity (e.g. 100% cleavage
extent in 4 h), experimentally demonstrated in this work.
This study demonstrates the catalytic properties of novel su-
pramolecular biomaterials against RNA molecules. This new
methodology provides the strong position for future development
of novel approaches for sequence-speciﬁc targeting of biologically-
signiﬁcant RNAs in order to facilitate the discovery of new selective
therapeutics against viral genomic RNAs and speciﬁc messenger
RNAs or miRNAs implicated in disease.Author contributions
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